Cesar Augusto Santa-Maria1, Jingsheng Yan, Xian-Jin Xie, David Michael Euhus. 1. Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Bunting-Blaustein Cancer Research Bldg, Johns Hopkins University, 1650 Orleans St., Rm. 144, Baltimore, MD, 21287-0013, USA, csantam2@jhmi.edu.
Abstract
BACKGROUND: Obese women with estrogen receptor (ER)-positive breast cancer may experience worse disease-free and overall survival. We hypothesize that this observation is due to intrinsically aggressive disease and that obesity will be associated with higher histologic grade and Ki67. METHODS: A sequential cohort of women with breast cancer diagnosed over 2 years was assembled from institutional tumor registries. Patient and tumor characteristics were abstracted from medical records; those with non-invasive tumors, or lacking body mass index (BMI), Ki67 or histologic grade data, were excluded. Univariate and multivariate analysis was performed to investigate the relationship between markers of aggressive disease (grade and Ki67) and multiple variables associated with obesity. A subgroup analysis was performed to investigate further whether ER and menopausal status influenced associations between BMI and aggressive phenotypes. RESULTS: Of the 1007 patients initially identified, 668 (68 %) met the eligibility criteria. In univariate analysis, histologic grade and Ki67 were strongly associated with increased BMI, younger age, and African-American race, but less so with diabetes, hypertension, and hyperlipidemia. Multivariate analysis confirmed that higher histologic grade was associated with increased BMI (p = 0.02), and that increased Ki67 was associated with younger age (p = 0.0003) and African-American race (p = 0.002). Additional analysis found that the association between increased BMI and higher-grade tumors was particularly significant in premenopausal women with ER-positive disease. CONCLUSION: This study concludes that increased BMI is associated with aggressive-phenotype breast cancer and may be particularly relevant to ER-positive breast cancer developing in premenopausal African-American women.
BACKGROUND:Obesewomen with estrogen receptor (ER)-positive breast cancer may experience worse disease-free and overall survival. We hypothesize that this observation is due to intrinsically aggressive disease and that obesity will be associated with higher histologic grade and Ki67. METHODS: A sequential cohort of women with breast cancer diagnosed over 2 years was assembled from institutional tumor registries. Patient and tumor characteristics were abstracted from medical records; those with non-invasive tumors, or lacking body mass index (BMI), Ki67 or histologic grade data, were excluded. Univariate and multivariate analysis was performed to investigate the relationship between markers of aggressive disease (grade and Ki67) and multiple variables associated with obesity. A subgroup analysis was performed to investigate further whether ER and menopausal status influenced associations between BMI and aggressive phenotypes. RESULTS: Of the 1007 patients initially identified, 668 (68 %) met the eligibility criteria. In univariate analysis, histologic grade and Ki67 were strongly associated with increased BMI, younger age, and African-American race, but less so with diabetes, hypertension, and hyperlipidemia. Multivariate analysis confirmed that higher histologic grade was associated with increased BMI (p = 0.02), and that increased Ki67 was associated with younger age (p = 0.0003) and African-American race (p = 0.002). Additional analysis found that the association between increased BMI and higher-grade tumors was particularly significant in premenopausal women with ER-positive disease. CONCLUSION: This study concludes that increased BMI is associated with aggressive-phenotype breast cancer and may be particularly relevant to ER-positive breast cancer developing in premenopausal African-American women.
Authors: Rowan T Chlebowski; Anne McTiernan; Jean Wactawski-Wende; JoAnn E Manson; Aaron K Aragaki; Thomas Rohan; Eli Ipp; Virginia G Kaklamani; Mara Vitolins; Robert Wallace; Marc Gunter; Lawrence S Phillips; Howard Strickler; Karen Margolis; David M Euhus Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Selina A Smith; Mechelle D Claridy; Mary S Whitehead; Joyce Q Sheats; Wonsuk Yoo; Ernest Alema-Mensah; Benjamin E Ansa; Ronald L Braithwaite Journal: J Ga Public Health Assoc Date: 2016
Authors: Yujing J Heng; Jun Wang; Thomas U Ahearn; Susan B Brown; Xuehong Zhang; Christine B Ambrosone; Victor Piana de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; Natalie C DuPre; Montserrat Garcia-Closas; Melissa A Troester; David J Hunter; A Heather Eliassen; Rulla M Tamimi; Susan E Hankinson; Andrew H Beck Journal: Breast Cancer Res Treat Date: 2018-11-01 Impact factor: 4.872
Authors: Mustapha Abubakar; Jenny Chang-Claude; H Raza Ali; Nilanjan Chatterjee; Penny Coulson; Frances Daley; Fiona Blows; Javier Benitez; Roger L Milne; Hermann Brenner; Christa Stegmaier; Arto Mannermaa; Anja Rudolph; Peter Sinn; Fergus J Couch; Peter Devilee; Rob A E M Tollenaar; Caroline Seynaeve; Jonine Figueroa; Jolanta Lissowska; Stephen Hewitt; Maartje J Hooning; Antoinette Hollestelle; Renée Foekens; Linetta B Koppert; Manjeet K Bolla; Qin Wang; Michael E Jones; Minouk J Schoemaker; Renske Keeman; Douglas F Easton; Anthony J Swerdlow; Mark E Sherman; Marjanka K Schmidt; Paul D Pharoah; Montserrat Garcia-Closas Journal: Int J Cancer Date: 2018-03-25 Impact factor: 7.396
Authors: Ximena M Bustamante-Marin; Jenna L Merlino; Emily Devericks; Meredith S Carson; Stephen D Hursting; Delisha A Stewart Journal: Front Endocrinol (Lausanne) Date: 2021-03-17 Impact factor: 6.055
Authors: Mustapha Abubakar; Changyuan Guo; Hela Koka; Bin Zhu; Joseph Deng; Nan Hu; Bin Zhou; Montserrat Garcia-Closas; Ning Lu; Xiaohong R Yang Journal: Breast Cancer Res Treat Date: 2021-06-29 Impact factor: 4.872